In vivo imaging of tau pathology using multi-parametric quantitative MRI

As the number of people diagnosed with Alzheimer's disease (AD) reaches epidemic proportions, there is an urgent need to develop effective treatment strategies to tackle the social and economic costs of this fatal condition. Dozens of candidate therapeutics are currently being tested in clinical trials, and compounds targeting the aberrant accumulation of tau proteins into neurofibrillary tangles (NFTs) are the focus of substantial current interest. Reliable, translatable biomarkers sensitive to both tau pathology and its modulation by treatment along with animal models that faithfully reflect aspects of the human disease are urgently required. Magnetic resonance imaging (MRI) is well established as a valuable tool for monitoring the structural brain changes that accompany AD progression. However the descent into dementia is not defined by macroscopic brain matter loss alone: non-invasive imaging measurements sensitive to protein accumulation, white matter integrity and cerebral haemodynamics probe distinct aspects of AD pathophysiology and may serve as superior biomarkers for assessing drug efficacy. Here we employ a multi-parametric array of five translatable MRI techniques to characterise the in vivo pathophysiological phenotype of the rTg4510 mouse model of tauopathy (structural imaging, diffusion tensor imaging (DTI), arterial spin labelling (ASL), chemical exchange saturation transfer (CEST) and glucose CEST). Tau-induced pathological changes included grey matter atrophy, increased radial diffusivity in the white matter, decreased amide proton transfer and hyperperfusion. We demonstrate that the above markers unambiguously discriminate between the transgenic group and age-matched controls and provide a comprehensive profile of the multifaceted neuropathological processes underlying the rTg4510 model. Furthermore, we show that ASL and DTI techniques offer heightened sensitivity to processes believed to precede detectable structural changes and, as such, provides a platform for the study of disease mechanisms and therapeutic intervention.

[1]  Thomas E. Nichols,et al.  Thresholding of Statistical Maps in Functional Neuroimaging Using the False Discovery Rate , 2002, NeuroImage.

[2]  J. Chin,et al.  Selecting a mouse model of Alzheimer's disease. , 2010, Methods in molecular biology.

[3]  D. Royall,et al.  Alzheimer disease as a vascular disorder: nosological evidence. , 2002, Stroke.

[4]  C. Jack,et al.  Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease , 1997, Neurology.

[5]  Seong-Gi Kim Quantification of relative cerebral blood flow change by flow‐sensitive alternating inversion recovery (FAIR) technique: Application to functional mapping , 1995, Magnetic resonance in medicine.

[6]  C. Jack,et al.  Mild cognitive impairment and Alzheimer disease: regional diffusivity of water. , 2001, Radiology.

[7]  M. Lythgoe,et al.  The importance of RF bandwidth for effective tagging in pulsed arterial spin labeling MRI at 9.4T , 2012, NMR in biomedicine.

[8]  R. Turner,et al.  Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Nick C Fox,et al.  The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.

[10]  Shu-Wei Sun,et al.  Detection of age-dependent brain injury in a mouse model of brain amyloidosis associated with Alzheimer's disease using magnetic resonance diffusion tensor imaging , 2005, Experimental Neurology.

[11]  B. Hyman,et al.  Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function , 2005, Science.

[12]  W. Bowers,et al.  Triple‐transgenic Alzheimer's disease mice exhibit region‐specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology , 2009, Glia.

[13]  Anatol C. Kreitzer,et al.  Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease , 2007, Neuron.

[14]  Yu-Ling Chang,et al.  Altered brain response for semantic knowledge in Alzheimer's disease , 2011, Neuropsychologia.

[15]  E. Roberson,et al.  Mouse models of Alzheimer's disease , 2012, Brain Research Bulletin.

[16]  F. Metzger,et al.  Cortical hypoperfusion in the B6.PS2APP mouse model for Alzheimer's disease: Comprehensive phenotyping of vascular and tissular parameters by MRI , 2009, Magnetic resonance in medicine.

[17]  Jayaram K. Udupa,et al.  New variants of a method of MRI scale standardization , 2000, IEEE Transactions on Medical Imaging.

[18]  C. Żekanowski,et al.  Mitochondrial dysfunction and Alzheimer's disease , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[19]  Matthias J. Müller,et al.  Ultrastructural Hippocampal and White Matter Alterations in Mild Cognitive Impairment: A Diffusion Tensor Imaging Study , 2004, Dementia and Geriatric Cognitive Disorders.

[20]  Naruhiko Sahara,et al.  Propagation of Tau Pathology in a Model of Early Alzheimer's Disease , 2012, Neuron.

[21]  C. Packer,et al.  Diagnosing Alzheimer’s disease: are we any nearer to useful biomarker-based, non-invasive tests? , 2013, GMS health technology assessment.

[22]  Xavier Golay,et al.  Imaging Brain Deoxyglucose Uptake and Metabolism by Glucocest MRI , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  Marie Kelly-Worden,et al.  Mitochondrial Dysfunction and Alzheimer’s Disease , 2013 .

[24]  Xiaolei Song,et al.  Nuts and bolts of chemical exchange saturation transfer MRI , 2013, NMR in biomedicine.

[25]  K. Ashe,et al.  Age-Dependent Neurofibrillary Tangle Formation, Neuron Loss, and Memory Impairment in a Mouse Model of Human Tauopathy (P301L) , 2005, The Journal of Neuroscience.

[26]  Clifford R Jack,et al.  Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. , 2012, Radiology.

[27]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[28]  Nirbhay N. Yadav,et al.  Chemical exchange saturation transfer (CEST): What is in a name and what isn't? , 2011, Magnetic resonance in medicine.

[29]  Efstathios D. Gennatas,et al.  Predicting Regional Neurodegeneration from the Healthy Brain Functional Connectome , 2012, Neuron.

[30]  Diane Stephenson,et al.  Volumetric MRI and MRS provide sensitive measures of Alzheimer's disease neuropathology in inducible Tau transgenic mice (rTg4510) , 2011, NeuroImage.

[31]  C. Jack,et al.  Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia , 2002, Neurology.

[32]  Yoshinori Kato,et al.  Natural D‐glucose as a biodegradable MRI contrast agent for detecting cancer , 2012, Magnetic resonance in medicine.

[33]  Sébastien Ourselin,et al.  Fast free-form deformation using graphics processing units , 2010, Comput. Methods Programs Biomed..

[34]  Lei Wang,et al.  Correlations Between Antemortem Hippocampal Volume and Postmortem Neuropathology in AD Subjects , 2004, Alzheimer disease and associated disorders.

[35]  S. Rose,et al.  Gray and white matter changes in Alzheimer's disease: A diffusion tensor imaging study , 2008, Journal of magnetic resonance imaging : JMRI.

[36]  F. Hentschel,et al.  Leistet die Magnetization-Transfer-Ratio (MTR) einen Beitrag zur Diagnostik und Differenzialdiagnostik der Demenzen? , 2004 .

[37]  D. Le Bihan,et al.  Diffusion tensor imaging: Concepts and applications , 2001, Journal of magnetic resonance imaging : JMRI.

[38]  John A Detre,et al.  Arterial spin labeling MRI: an emerging biomarker for Alzheimer's disease and other neurodegenerative conditions. , 2012, Current opinion in neurology.

[39]  M. Damian,et al.  [Does magnetization transfer ratio (MTR) contribute to the diagnosis and differential diagnosis of the dementias?]. , 2004, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[40]  Sébastien Ourselin,et al.  STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcelation , 2013, Medical Image Anal..

[41]  Jefferson W. Kinney,et al.  Alzheimer's disease biomarkers: Correspondence between human studies and animal models , 2013, Neurobiology of Disease.

[42]  A. Connelly,et al.  Anisotropic noise propagation in diffusion tensor MRI sampling schemes , 2003, Magnetic resonance in medicine.

[43]  F. Admiraal-Behloul,et al.  Magnetization transfer imaging of gray and white matter in mild cognitive impairment and Alzheimer's disease , 2006, Neurobiology of Aging.

[44]  C Caltagirone,et al.  When, where, and how the corpus callosum changes in MCI and AD , 2010, Neurology.

[45]  John Russell,et al.  Dysmyelination Revealed through MRI as Increased Radial (but Unchanged Axial) Diffusion of Water , 2002, NeuroImage.

[46]  Richard J. Caselli,et al.  Ushering in the study and treatment of preclinical Alzheimer disease , 2013, Nature Reviews Neurology.

[47]  C. Rampon,et al.  Impaired neurogenesis, neuronal loss, and brain functional deficits in the APPxPS1-Ki mouse model of Alzheimer's disease , 2011, Neurobiology of Aging.

[48]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[49]  Alan C. Evans,et al.  A nonparametric method for automatic correction of intensity nonuniformity in MRI data , 1998, IEEE Transactions on Medical Imaging.

[50]  C. Rae,et al.  Glutamate Metabolism is Impaired in Transgenic Mice with Tau Hyperphosphorylation , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[51]  Sheng-Kwei Song,et al.  Diffusion tensor imaging detects age-dependent white matter changes in a transgenic mouse model with amyloid deposition , 2004, Neurobiology of Disease.

[52]  J. Trojanowski,et al.  Neurodegenerative tauopathies. , 2001, Annual review of neuroscience.

[53]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[54]  Clifford R. Jack,et al.  Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage , 2008, NeuroImage.

[55]  M. Weiner,et al.  A Network Diffusion Model of Disease Progression in Dementia , 2012, Neuron.

[56]  C. Jack,et al.  MRI correlates of neurofibrillary tangle pathology at autopsy , 2008, Neurology.

[57]  Martin Beibel,et al.  Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.

[58]  J B Langbaum Correction: Ushering in the study and treatment of preclinical Alzheimer disease , 2013 .

[59]  S Warach,et al.  A general kinetic model for quantitative perfusion imaging with arterial spin labeling , 1998, Magnetic resonance in medicine.

[60]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[61]  P. T. Nguyen,et al.  Dendritic Spine Abnormalities in Amyloid Precursor Protein Transgenic Mice Demonstrated by Gene Transfer and Intravital Multiphoton Microscopy , 2005, The Journal of Neuroscience.

[62]  Naruhiko Sahara,et al.  Age-related decline in white matter integrity in a mouse model of tauopathy: an in vivo diffusion tensor magnetic resonance imaging study , 2014, Neurobiology of Aging.

[63]  Mark F. Lythgoe,et al.  In vivo imaging of glucose uptake and metabolism in tumors , 2012, Nature Medicine.

[64]  A. Dale,et al.  Regional rates of neocortical atrophy from normal aging to early Alzheimer disease , 2009, Neurology.